Search research articles
Contact Us
Filters
Showing results (21-30 of 29) with videos related to
Page
of 3
Sort By:
You have reached the last page of results.
This site can display upto 29 results.
Cell Death & Disease
|
January 6, 2026
Dual Bcl-2/Bcl-xl inhibition via AZD0466 combines with immune checkpoint blockade to enhance anti-tumour activity
Dane M Newman, Courtney L Andersen, Leonie A Cluse, et al.
Journal of Cardiovascular Pharmacology and Therapeutics
|
May 18, 2018
Comparison of LDL-C Reduction Using Different Evolocumab Doses and Intervals: Biological Insights and Treatment Implications
Scott M Wasserman, Marc S Sabatine, Michael J Koren, et al.
Clinical Epidemiology
|
December 3, 2011
Use of electronic medical records (EMR) for oncology outcomes research: assessing the comparability of EMR information to patient registry and health claims data
Edmund C Lau, Fionna S Mowat, Michael A Kelsh, et al.
JAMA
|
May 15, 2014
Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial
Jennifer G Robinson, Bettina S Nedergaard, William J Rogers, et al.
Clinical Cardiology
|
February 1, 2014
Rationale and design of LAPLACE-2: a phase 3, randomized, double-blind, placebo- and ezetimibe-controlled trial evaluating the efficacy and safety of evolocumab in subjects with hypercholesterolemia on background statin therapy
Jennifer G Robinson, William J Rogers, Bettina S Nedergaard, et al.
JACC. Heart Failure
|
February 10, 2020
Omecamtiv Mecarbil in Chronic Heart Failure With Reduced Ejection Fraction: Rationale and Design of GALACTIC-HF
John R Teerlink, Rafael Diaz, G Michael Felker, et al.
European Journal of Heart Failure
|
April 7, 2021
The effect of the cardiac myosin activator, omecamtiv mecarbil, on right ventricular structure and function in chronic systolic heart failure (COSMIC-HF)
Tor Biering-Sørensen, Masatoshi Minamisawa, Jiankang Liu, et al.
European Journal of Heart Failure
|
September 28, 2020
Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: GALACTIC-HF baseline characteristics and comparison with contemporary clinical trials
John R Teerlink, Rafael Diaz, G Michael Felker, et al.
The New England Journal of Medicine
|
November 13, 2020
Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure
John R Teerlink, Rafael Diaz, G Michael Felker, et al.
Page
of 3
Search research articles
Search
Showing results (21-30 of 29) with videos related to
Sort By:
Page
of 3
You have reached the last page of results.
This site can display upto 29 results.
Cell Death & Disease
|
January 6, 2026
Dual Bcl-2/Bcl-xl inhibition via AZD0466 combines with immune checkpoint blockade to enhance anti-tumour activity
Dane M Newman, Courtney L Andersen, Leonie A Cluse, et al.
Journal of Cardiovascular Pharmacology and Therapeutics
|
May 18, 2018
Comparison of LDL-C Reduction Using Different Evolocumab Doses and Intervals: Biological Insights and Treatment Implications
Scott M Wasserman, Marc S Sabatine, Michael J Koren, et al.
Clinical Epidemiology
|
December 3, 2011
Use of electronic medical records (EMR) for oncology outcomes research: assessing the comparability of EMR information to patient registry and health claims data
Edmund C Lau, Fionna S Mowat, Michael A Kelsh, et al.
JAMA
|
May 15, 2014
Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial
Jennifer G Robinson, Bettina S Nedergaard, William J Rogers, et al.
Clinical Cardiology
|
February 1, 2014
Rationale and design of LAPLACE-2: a phase 3, randomized, double-blind, placebo- and ezetimibe-controlled trial evaluating the efficacy and safety of evolocumab in subjects with hypercholesterolemia on background statin therapy
Jennifer G Robinson, William J Rogers, Bettina S Nedergaard, et al.
JACC. Heart Failure
|
February 10, 2020
Omecamtiv Mecarbil in Chronic Heart Failure With Reduced Ejection Fraction: Rationale and Design of GALACTIC-HF
John R Teerlink, Rafael Diaz, G Michael Felker, et al.
European Journal of Heart Failure
|
April 7, 2021
The effect of the cardiac myosin activator, omecamtiv mecarbil, on right ventricular structure and function in chronic systolic heart failure (COSMIC-HF)
Tor Biering-Sørensen, Masatoshi Minamisawa, Jiankang Liu, et al.
European Journal of Heart Failure
|
September 28, 2020
Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: GALACTIC-HF baseline characteristics and comparison with contemporary clinical trials
John R Teerlink, Rafael Diaz, G Michael Felker, et al.
The New England Journal of Medicine
|
November 13, 2020
Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure
John R Teerlink, Rafael Diaz, G Michael Felker, et al.
Page
of 3